Lineage Cell Therapeutics, Inc.

LCTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-5.1M
Depreciation & Amortization
Depreciation $34.6K
Amortization $0
Stock-Based Compensation $260.8K
Net Cash from Operating Activities $-4.3M
Investing Activities
Capital Expenditures $61.3K
Business Acquisitions $0
Net Cash from Investing Activities $-46.2K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $16.5M
Net Change in Cash $12.2M
Free Cash Flow $-4.3M
← Newer Page 3 of 3 Older →